Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial
- 1McMaster University and Hamilton Health Sciences, Department of Medicine, Hamilton, Ontario L8N 3Z5, Canada. gerstein@mcmaster.ca
- 0McMaster University and Hamilton Health Sciences, Department of Medicine, Hamilton, Ontario L8N 3Z5, Canada. gerstein@mcmaster.ca
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Rosiglitazone did not significantly slow coronary atherosclerosis progression compared to glipizide in type 2 diabetes patients. However, rosiglitazone did reduce normalized total atheroma volume, a secondary outcome.
Area Of Science
- Cardiology
- Endocrinology
- Pharmacology
Background
- Rosiglitazone, a thiazolidinedione, possesses properties that may influence atherosclerosis progression.
- The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History (APPROACH) study was designed to investigate these effects.
Purpose Of The Study
- To determine the effect of rosiglitazone on coronary atherosclerosis progression compared to glipizide in patients with type 2 diabetes and a history of cardiovascular disease.
- To assess changes in atheroma volume using intravascular ultrasound.
Main Methods
- A randomized, double-blind, 18-month controlled study involving 672 patients with type 2 diabetes and coronary atherosclerosis.
- Patients were treated with lifestyle modifications, one oral agent, or submaximal doses of two oral agents.
- The primary outcome was the change in percent atheroma volume in a non-intervened epicardial coronary artery.
Main Results
- Rosiglitazone did not significantly reduce the primary outcome of percent atheroma volume compared to glipizide (P=0.12).
- A significant reduction in normalized total atheroma volume was observed with rosiglitazone compared to glipizide (P=0.04).
- No significant difference was found in the change of total atheroma volume in the most diseased 10-mm segment between the groups (P=0.13).
Conclusions
- Rosiglitazone did not significantly decrease the primary endpoint of coronary atherosclerosis progression compared to glipizide in patients with type 2 diabetes mellitus.
- The study provides insights into the differential effects of these diabetes medications on atherosclerotic burden.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.